119 related articles for article (PubMed ID: 11071457)
1. Molecular analysis of mechanisms regulating drug sensitivity and the development of new chemotherapy strategies for genitourinary carcinomas.
Naito S; Koga H; Yokomizo A; Sakamoto N; Kotoh S; Nakashima M; Kiue A; Kuwano M
World J Surg; 2000 Oct; 24(10):1183-6. PubMed ID: 11071457
[TBL] [Abstract][Full Text] [Related]
2. Mechanisms of drug resistance in chemotherapy for urogenital carcinoma.
Naito S; Yokomizo A; Koga H
Int J Urol; 1999 Sep; 6(9):427-39. PubMed ID: 10510888
[TBL] [Abstract][Full Text] [Related]
3. Circumvention of multidrug resistance in genitourinary tumors.
van Brussel JP; Mickisch GH
Int J Urol; 1998 Jan; 5(1):1-15. PubMed ID: 9535594
[TBL] [Abstract][Full Text] [Related]
4. Clinical reversal of drug resistance.
Goldstein LJ
Curr Probl Cancer; 1995; 19(2):65-124. PubMed ID: 7600845
[TBL] [Abstract][Full Text] [Related]
5. Molecular mechanisms of multidrug resistance in cancer chemotherapy.
Nooter K; Stoter G
Pathol Res Pract; 1996 Jul; 192(7):768-80. PubMed ID: 8880878
[TBL] [Abstract][Full Text] [Related]
6. Expression of multidrug resistance-associated protein (MRP), MDR1 and DNA topoisomerase II in human multidrug-resistant bladder cancer cell lines.
Hasegawa S; Abe T; Naito S; Kotoh S; Kumazawa J; Hipfner DR; Deeley RG; Cole SP; Kuwano M
Br J Cancer; 1995 May; 71(5):907-13. PubMed ID: 7734314
[TBL] [Abstract][Full Text] [Related]
7. Decreased mutation rate for cellular resistance to doxorubicin and suppression of mdr1 gene activation by the cyclosporin PSC 833.
Beketic-Oreskovic L; Durán GE; Chen KG; Dumontet C; Sikic BI
J Natl Cancer Inst; 1995 Nov; 87(21):1593-602. PubMed ID: 7563202
[TBL] [Abstract][Full Text] [Related]
8. Development of novel reversal agents, imidazothiazole derivatives, targeting MDR1- and MRP-mediated multidrug resistance.
Naito S; Koike K; Ono M; Machida T; Tasaka S; Kiue A; Koga H; Kumazawa J
Oncol Res; 1998; 10(3):123-32. PubMed ID: 9700723
[TBL] [Abstract][Full Text] [Related]
9. Expression patterns of multidrug-resistance (MDR1), multidrug resistance-associated protein (MRP),glutathione-S-transferase-pi (GST-pi) and DNA topoisomerase II (Topo II) genes in renal cell carcinomas and normal kidney.
Kim WJ; Kakehi Y; Kinoshita H; Arao S; Fukumoto M; Yoshida O
J Urol; 1996 Aug; 156(2 Pt 1):506-11. PubMed ID: 8683726
[TBL] [Abstract][Full Text] [Related]
10. Recent advances in P-glycoprotein-mediated multidrug resistance reversal mechanisms.
Li X; Li JP; Yuan HY; Gao X; Qu XJ; Xu WF; Tang W
Methods Find Exp Clin Pharmacol; 2007 Nov; 29(9):607-17. PubMed ID: 18193112
[TBL] [Abstract][Full Text] [Related]
11. New silicon compounds as resistance modifiers against multidrug-resistant cancer cells.
Molnar J; Mucsi I; Nacsa J; Hevér A; Gyémánt N; Ugocsai K; Hegyes P; Kiessig S; Gaal D; Lage H; Varga A
Anticancer Res; 2004; 24(2B):865-71. PubMed ID: 15161039
[TBL] [Abstract][Full Text] [Related]
12. Functional multidrug resistance phenotype associated with combined overexpression of Pgp/MDR1 and MRP together with 1-beta-D-arabinofuranosylcytosine sensitivity may predict clinical response in acute myeloid leukemia.
Schuurhuis GJ; Broxterman HJ; Ossenkoppele GJ; Baak JP; Eekman CA; Kuiper CM; Feller N; van Heijningen TH; Klumper E; Pieters R
Clin Cancer Res; 1995 Jan; 1(1):81-93. PubMed ID: 9815890
[TBL] [Abstract][Full Text] [Related]
13. Expression of multidrug resistance-associated proteins in paediatric soft tissue sarcomas before and after chemotherapy.
Citti A; Boldrini R; Inserra A; Alisi A; Pessolano R; Mastronuzzi A; Zin A; De Sio L; Rosolen A; Locatelli F; Fruci D
Int J Oncol; 2012 Jul; 41(1):117-24. PubMed ID: 22504834
[TBL] [Abstract][Full Text] [Related]
14. Chemosensitisation of spontaneous multidrug resistance by a 1,4-dihydropyridine analogue and verapamil in human glioma cell lines overexpressing MRP or MDR1.
Abe T; Koike K; Ohga T; Kubo T; Wada M; Kohno K; Mori T; Hidaka K; Kuwano M
Br J Cancer; 1995 Aug; 72(2):418-23. PubMed ID: 7640227
[TBL] [Abstract][Full Text] [Related]
15. The role of topotecan for extending the platinum-free interval in recurrent ovarian cancer: an in vitro model.
Horowitz NS; Hua J; Gibb RK; Mutch DG; Herzog TJ
Gynecol Oncol; 2004 Jul; 94(1):67-73. PubMed ID: 15262121
[TBL] [Abstract][Full Text] [Related]
16. Altered MRP is associated with multidrug resistance and reduced drug accumulation in human SW-1573 cells.
Eijdems EW; Zaman GJ; de Haas M; Versantvoort CH; Flens MJ; Scheper RJ; Kamst E; Borst P; Baas F
Br J Cancer; 1995 Aug; 72(2):298-306. PubMed ID: 7640209
[TBL] [Abstract][Full Text] [Related]
17. Expression of multidrug resistance-related genes (mdrl, MRP, GST-pi and DNA topoisomerase II) in urothelial cancers.
Kim WJ; Kakehi Y; Wu WJ; Fukumoto M; Yoshida O
Br J Urol; 1996 Sep; 78(3):361-8. PubMed ID: 8881943
[TBL] [Abstract][Full Text] [Related]
18. Role of glutathione, glutathione S-transferases and multidrug resistance-related proteins in cisplatin sensitivity of head and neck cancer cell lines.
Welters MJ; Fichtinger-Schepman AM; Baan RA; Flens MJ; Scheper RJ; Braakhuis BJ
Br J Cancer; 1998 Feb; 77(4):556-61. PubMed ID: 9484811
[TBL] [Abstract][Full Text] [Related]
19. Expression of the MRP and MDR1 multidrug resistance genes in small cell lung cancer.
Campling BG; Young LC; Baer KA; Lam YM; Deeley RG; Cole SP; Gerlach JH
Clin Cancer Res; 1997 Jan; 3(1):115-22. PubMed ID: 9815546
[TBL] [Abstract][Full Text] [Related]
20. Comparison of multidrug resistance gene expression levels with malignant potentials and influence of chemotherapy in urothelial cancers.
Kakehi Y; Wu WJ; Kim WJ; Arao S; Fukumoto M; Yoshida O
Int J Urol; 1995 Nov; 2(5):309-15. PubMed ID: 8749949
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
